BMS and zaiding pharmaceutical sign the brivanib license agreement

Bristol Myers Squibb (NYSE Code: BMY) and China's leading innovative pharmaceutical company Zai lab today jointly announced that they have signed an agreement that zaidin will have the exclusive right to develop, produce and promote brivanib in Greater China, including Hong Kong and Macao Blinib is an oral kinase inhibitor, which is mainly used in the treatment of HCC and other solid tumors Now it is in the global phase III clinical trials Zaiding pharmaceutical will be responsible for the development, production and commercial promotion of brineb in China Bristol Myers Squibb will be eligible to receive milestone payments for different stages of development and a share of its approved commercial sales ladder Bristol Myers Squibb also has the option to work with zaiding Pharmaceutical Co., Ltd to promote and share the commercial profits of brineb in China Bristol Myers Squibb reserves all development and commercial rights of the brineb outside China The remaining terms are not disclosed "HCC is the most common type of primary liver cancer Generally speaking, patients diagnosed as intermediate stage HCC can only survive for 20 months," said Karl lintel, President of Bristol Myers Squibb China We are very pleased to cooperate with zaiding pharmaceutical to further develop as a treatment scheme in Chinese patients with HCC Early clinical trials have shown that in patients with advanced HCC who do not respond to other therapies, it may delay the progression of the disease "We are very excited about this cooperation," said Samantha Du, founder and CEO of zaiding pharmaceutical Brinib has been tested in a number of global phase III trials, involving many Chinese patients with HCC In Chinese patients with HCC, encouraging data were observed in an acceptable range of safety More than half of the world's new liver cancer patients come from China, with 400000 new cases and 371000 deaths in 2012 Based on the preliminary analysis of a large number of three-phase clinical data, it is expected that brinib will provide a new treatment option for Chinese patients with HCC "